Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. - Wikidata - thesis-toulmin - TriplyDB

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

http://www.wikidata.org/entity/Q34267472

about

Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma Oral human papillomavirus infection and head and neck cancers in HIV-infected individuals EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women.Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review.Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.Human papillomavirus seropositivity and subsequent risk of HIV acquisition in rural South African women The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults.A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus The impact of HPV female immunization in Italy: model based predictions.Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia.Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females The known unknowns of HPV natural history.Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.Epithelial cell responses to infection with human papillomavirus.Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica A review of clinical trials of human papillomavirus prophylactic vaccines.Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic.Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women.Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.

P2860

Q26782499-9C26CC45-403E-4C0A-98B3-D8A107D7BDDA Q26825257-CE3A01AD-6A35-4266-B3CF-0FB379D4EBBD Q27010432-3DA79B9D-414E-464D-B71C-0F2E17785E42 Q27347744-A70CCA7B-3F40-40BE-BA56-E5DEA66BCFEC Q30300329-F7E09248-9B60-45AA-8937-1B5DA155AC3E Q30354637-80B1DE48-8D10-4044-9E0F-93A410DAD065 Q33665786-26B45C63-D827-4F32-B3D3-D95BF04280A1 Q33770030-5F81C171-BB1D-4BF3-ABD5-1E0344610E96 Q33947813-DF8FB61E-C361-47BD-8341-CECB4A14D098 Q33953881-0A672098-9E62-4502-B1AD-C053B10DD775 Q34199560-9D857ACC-7E1B-439C-85CA-B535FB4772E0 Q34542304-A1203D5A-52B9-4EBF-8A68-25CBE598A692 Q34546550-470EFDF8-41BD-40C9-AAE7-05CCC2DA922B Q34551969-7350E483-24AE-44A8-ABEF-C850B06A4CC6 Q34583160-E7668436-4C89-4307-AE8E-2766FF7FADD1 Q34882577-4EA0D527-97C6-48C1-ACA4-4A4F4BA61025 Q34970731-B6F06B28-3B68-4191-99AE-787CBD480183 Q34994905-59EE3C05-972C-48ED-A966-6541FF47881C Q35088658-7C2EF18D-859D-40B4-A0C7-13B94B758B0F Q35109451-15B76F37-78A2-48CF-82B6-9F2E0B702A42 Q35117850-886B0EF9-DB3C-4ED0-A9A8-ADC01B568F14 Q35221196-C46B0B78-D1BE-46A0-A4A5-96B7A2589627 Q35268615-580F8F42-1352-4204-B964-3AB021F5812B Q35550810-E4F26851-752D-4C10-AB84-5624D87C4AF9 Q35578583-C9BB7E22-794B-4A15-A789-829EFD8E2081 Q35810353-59124C00-6D6E-4F8C-A182-7D0AFCF3204C Q35861286-181D270A-6314-48F6-9BB1-D3C1A8B171DA Q35886468-77AFFC05-FD95-4184-A4CF-C579BA45A526 Q35886910-E17FB9DF-2291-4B65-9EB5-565C4B410002 Q35918834-D86D0616-72D5-4D8A-BE04-ABB8D9DAF23B Q35940596-91AC35DE-3CE5-43E0-ABE2-69DFC59B25DB Q35967430-45CB8859-3D5B-48ED-B35D-88BFA3421211 Q36259403-D450AB1A-BA8F-4C3D-96B5-89A227C1E72B Q36327051-3D8AB548-0C00-4DD3-9D2A-70E2A5C214EE Q36379269-679BC1D4-47F9-4855-9E82-003EC7B3C290 Q36677322-6B5E3A6E-F0D7-4564-B403-E256BF19E6F8 Q36745242-B2CAE4D4-4417-4FD1-B019-E39E5329DAAB Q36921606-7E158631-59D7-4DA5-9F1C-87988A58CEB3 Q36964366-07D6C629-6A84-4B43-BFE5-EEFB3692AE44 Q36974917-1E417095-1095-4A77-B8F0-5776309ECFEA

P2860

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

http://www.wikidata.org/entity/Q34267472

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@ast

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@en

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@nl

type

label

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@ast

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@en

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@nl

prefLabel

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@ast

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@en

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@nl

P1433

Q34267472-75172D9C-CB35-4A2F-BE1B-8407D4CA7D87

P1476

Q34267472-BDD59587-55A1-4A9F-B45F-7E90B68821DB

P2093

Q34267472-78A81175-C47C-460D-83CE-2CF76695F00A

Q34267472-A6A987D9-EE6A-4629-9CDB-88486C3E8343

Q34267472-C16D835E-92BF-4E02-9B72-878D4B31F157

Q34267472-C2261F51-6792-4F18-A8DA-20A2155E9D36

Q34267472-DD718822-D178-4CB0-BCF3-4BFDB68E4A2B

Q34267472-EBD71A7C-1749-497C-8E2B-8123B9BC8B42

Q34267472-F96E16D8-0BB9-4EBE-89DF-86F00945A753

P2860

Q34267472-06B9F8B6-C109-4559-86EB-1E186E6C888B

Q34267472-1A854F5F-4A03-4CA1-A16F-42C87FD5F84A

Q34267472-2A493288-9966-4A08-8C1D-680304139536

Q34267472-2B4CA823-FE5A-47B0-BBB7-092950F135E1

Q34267472-2C1B5855-4F19-48F1-87D9-787D724FD0DA

Q34267472-38504655-1C17-46D5-8E3C-C78ACF12D1F7

Q34267472-48ABD407-CB96-41EE-ACCF-547191C9B0EC

Q34267472-5D7B0718-7701-47E8-B280-3B051E466FFC

Q34267472-6204CC83-F92C-438F-A945-FCF66A624804

Q34267472-9D24E1AD-3786-4E04-ACC9-7A7ADAEDE37E

P304

Q34267472-B61FF998-BB32-40F1-BB18-BF57A499F928

P31

Q34267472-32EFCF10-FA9B-4BFB-8538-A8D1062BB225

P356

Q34267472-C4289E2D-F1A2-4A2E-92B4-2244CDD037DE

P407

Q34267472-EF5D1941-2D6A-4778-96F0-175712C8E409

P433

Q34267472-13A93982-DE41-44B0-B2A5-A637812C5DA6

P478

Q34267472-66A33EF2-DB73-4061-838B-CEF9E3805CEB

P50

Q34267472-2AD60716-B869-4F60-9F04-A859AD86FB2C

Q34267472-682F409E-8A24-492B-A2F8-2581A2AFE848

Q34267472-9946EEA3-98E7-4D47-9E66-523DDA37280D

Q34267472-A86E186E-45D9-4996-8692-7D827822364E

Q34267472-BCDADBD0-8B47-4082-BBF3-243449EC9E66

Q34267472-FBA7C253-E865-4979-B38F-FB65BCE3FC8C

P577

Q34267472-F1DFAD47-E8FF-4A5F-A1AE-34BE819FCA7F

P5875

Q34267472-EE6AC5D4-7F5E-4E64-885B-59EF5AF0291B

P698

Q34267472-C3CB66A8-D2DD-4353-94CE-B3719C9993A2

P921

Q34267472-20F606A6-39E1-4822-9B37-6C4DE70FB9EE

P932

Q34267472-1FEBC3D8-6832-447B-94A8-CEF4A1C7F5A1

P356

P1433

Journal of the National Cancer Institute

P1476

Epidemiological study of anti- ...... k of HPV16 and -18 infections.

@en

P2093

Carolina Porras

http://www.w3.org/2001/XMLSchema#string

Costa Rican Vaccine Trial Group

http://www.w3.org/2001/XMLSchema#string

Mark E Sherman

http://www.w3.org/2001/XMLSchema#string

Paula Gonzalez

http://www.w3.org/2001/XMLSchema#string

Rolando Herrero

http://www.w3.org/2001/XMLSchema#string

Valérie Xhenseval

http://www.w3.org/2001/XMLSchema#string

Wim Quint

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

P304

1653-1662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJQ384

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Sholom Wacholder

Allan Hildesheim

Ana Cecilia Rodríguez

Leen-Jan van Doorn

Mahboobeh Safaeian

P577

2010-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47414996

http://www.w3.org/2001/XMLSchema#string

P698

20944077

http://www.w3.org/2001/XMLSchema#string

P921

P932

2970577

http://www.w3.org/2001/XMLSchema#string